Sign Out
Montelukast is the substrate of CYP2C8 (minor), CYP2C9 (minor), CYP3A4 (minor). Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Montelukast inhibits CYP2C8 (weak), CYP2C9 (weak).
Avoid concomitant use of Montelukast with Loxapine.
Montelukast may increase the levels/effects of Loxapine.
The levels/effects of Montelukast may be increased by Gemfibrozil.
The levels/effects of Montelukast may be decreased by Lumacaftor.
Continue with Google